// App-Quantinova.ai

565 : Neoadjuvant gemcitabine, docetaxel, and capecitabine results in comparable surgical outcomes to modified FOLFIRINOX in patients with pancreatic ductal adenocarcinoma who also receive radiation: A single institution experience.

Researchers

Presenter

  • Winston Wong

Principal Investigators

  • Jacob K.R. Jamison

  • Michael S. May

  • Alissa Michel

  • Tristan Lee

  • David Manrique

  • Alexander Raufi

  • Samuel M Pan

  • Rachael A Safyan

  • David Paul Horowitz

  • Beth Schrope

  • Michael Kluger

  • Lisa A. Kachnic

  • Jianhua Hu

  • Susan Elaine Bates

  • John A. Chabot

  • Gulam Abbas Manji

Medical Centers

  • Columbia University Medical Center, New York, NY

  • Columbia University Medical Center, New York, NY

  • Columbia University Medical Center, New York, NY

  • Lifespan Cancer Center, Providence, RI

  • Department of Radiation Oncology, Columbia University Irving Medical Center, New York, NY

  • Columbia University Medical Center, New York-Presbyterian Hospital, New York, NY

  • Columbia University Medical Center and Herbert Irving Comprehensive Cancer Center, New York, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Pancreas ductal adenocarcinoma

  • Microphthalmia, syndromic, 9

Biomarkers

  • N/A

Drug/Treatment

  • Capecitabine

  • Gemcitabine

  • FOLFIRINOX

  • Docetaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved